Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Nippon Kayaku To Restart Hycamtin Trial For Ovarian Cancer

This article was originally published in PharmAsia News

Executive Summary

Nippon Kayaku will restart a clinical trial in Japan for Hycamtin (topotecan) to treat ovarian cancer. The trial is to move forward a NDA submitted by the company to Japan's Ministry of Health, Labor and Welfare May 2007. Last October, the company was notified to submit additional data. Developed by GlaxoSmithKline, topotecan was approved to treat small-cell lung cancer in Japan in 2001 and Nippon Kayaku licensed the drug from GSK in 2003. The annual sales for Hycamtin in Japan are ¥100 million. (Click here for more - Japanese language

Table

View full table

Tags:
Latest Headlines

Executives On The Move: Three New CEOs Among This Week's Changes

Sanofi To Pursue Smart M&A Pacts And Stick With Early-Stage Oncology R&D

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

Biogen Sees Improving Momentum In Slow Leqembi Launch

See All
UsernamePublicRestriction

Register

SC071244

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By